Skip to content
drillr.ai

SNDX

Syndax Pharmaceuticals, Inc.

NASDAQ · USHealthcareBiotechnology
$22.29-2.24%

Price as of Jul 20, 2026

SNDX news

Syndax Pharmaceuticals, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2026, the Company granted inducement awards to purchase up to 250,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement

    Globe Newswire ·

  2. Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

    – Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or KMT2Ar AML shows 97% (34/35) CRc and 86% (25/29) MRD negativity among CRc responders – – Post-hoc analysis of patients with R/R NPM1m, KMT2Ar, or NUP98r acute leukemia in the AUGMENT-101 trial who resumed revumenib post-HSCT shows an observed 1-yea

    Globe Newswire ·

  3. Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

    – Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of 90% vs historical benchmark of 51% – – Company also presented data highlighting unique aspects of revumenib’s PK profile, including the ability to administer it with gastric acid reducing agents without the risk of reduced efficacy – NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceutical

    Globe Newswire ·

  4. Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

    – Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring unique aspects of revumenib’s PK profile, including the ability to administer it with gastric acid reducing agents and low-fat meals, will be presented – – Design of ongoing pivotal trials of revumenib plus low or high-intensity chemotherapy in newly diagnosed NPM1m or KMT2Ar acute leukemia will be

    Globe Newswire ·

  5. Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

    – Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj(®) (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R NPM1m AML – – Niktimvo™ (axatilimab-csfr) net revenue of $55.1 million in 1Q26, resulting in Syndax collaboration revenue of $15.9 million – – New revumenib real-world, frontline, and post-HSCT maintenance data anticipated in 2Q26 – – Topline data expected in 4Q26 from Phase 2 trials

    Globe Newswire ·